Tanke Biosciences Corp.

As of September 30, 2013, Tanke Biosciences Corp. carries a market capitalization of 2.66M, placing it among publicly traded companies globally. Its enterprise value stands at 7.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2013, Tanke Biosciences Corp. has 13.32M shares outstanding.

These figures are as of September 30, 2013. The price-to-sales ratio is 0.12, and the price-to-book ratio stands at 0.17.

As of September 30, 2013, Tanke Biosciences Corp. trades at an EV/EBITDA multiple of 8.84 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.11M versus a market cap of 2.66M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2013, Tanke Biosciences Corp. maintains a current ratio of 1.61, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 59.71, indicating elevated leverage, while an interest coverage ratio of 1.25 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2013, Tanke Biosciences Corp. posted a negative return on equity (ROE) of -10.22, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -5.69, reflecting losses generated across the asset base. The company generates approximately 176,616.78 in revenue per employee across its workforce of 130.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 9.46 indicates how many times Tanke Biosciences Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2013, Tanke Biosciences Corp. recorded 237,590.00 in income tax expense. The company reported a pretax loss of -1.44M and -1.64M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 7, 2026, Tanke Biosciences Corp.'s stock has declined approximately 44.20% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.03.

Over the twelve months ended September 30, 2013, Tanke Biosciences Corp. generated 22.96M in revenue and converted that into -1.64M in net income, yielding earnings per share of -0.13. EBITDA reached 804,294.00, while operating income came in at -57,268.00.

As of September 30, 2013, Tanke Biosciences Corp. holds 5.09M in cash and equivalents against 9.38M in total debt, resulting in a net debt position of 4.29M. Total book value stands at 15.56M, with working capital of 7.46M providing operational flexibility.

Tanke Biosciences Corp. produced -3.78M in operating cash flow over the twelve months ended September 30, 2013. After subtracting -2.53M in capital expenditures, free cash flow totaled -6.31M - equivalent to -0.47 per share.

Over the twelve months ended September 30, 2013, Tanke Biosciences Corp. posted a gross margin of 32.28, reflecting its pricing power and cost economics. The operating margin of -0.25 and net profit margin of -7.15 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2013. Free cash flow yield is negative at -236.94: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 3.55, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Tanke Biosciences Corp. shareholders.

Tanke Biosciences Corp.'s most recent stock split took place on February 10, 2011.

As of September 30, 2013, Tanke Biosciences Corp. has an Altman Z-Score of 1.35, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.